Result of AGM

RNS Number : 3874C

Synairgen plc

18 June 2021

 

Press release

Synairgen plc

('Synairgen' or the 'Company')

Result of AGM

Southampton, UK - 18 June 2021: Synairgen plc (LSE: SNG), is pleased to announce that all resolutions proposed at its Annual General Meeting, held earlier today, were duly passed.

The full results of the proxy voting can be found on the Company's website here .

A replay of the AGM webinar is now available here .

-Ends-

For further enquiries, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Chief Financial Officer

Tel: + 44 (0) 23 8051 2800

finnCap (NOMAD and Joint Broker)

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Sunil de Silva (ECM)

Tel: + 44 (0) 20 7220 0500

Numis Securities Limited (Joint Broker)

James Black, Freddie Barnfield, Duncan Monteith

Tel: + 44 (0) 20 7260 1000

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Jessica Hodgson, Carina Jurs

[e-mail]  

Tel: [phone]

MKC Strategies, LLC (US Media Relations)

Mary Conway

[e-mail]  

Tel: [phone]

Notes for Editors

About Synairgen  

Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.

Synairgen is currently focused on developing its product candidate, SNG001 (inhaled interferon beta) for the treatment of COVID-19. SNG001 is potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. The Company is evaluating nebulised SNG001 in its Phase III clinical programme, which has been deemed an Urgent Public Health study by the UK's National Institute for Health Research (NIHR). SNG001 has also been granted Fast Track status from the US Food and Drug Administration (FDA). In a Phase II trial, COVID-19 patients with marked/severe breathlessness demonstrated a threefold greater chance of recovery when treated with SNG001 versus placebo.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com  

 

END

 

 

RAGZZGMVLRNGMZG